Butallylonal: Difference between revisions
Appearance
Content deleted Content added
Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL. |
m Removing from Category:GABAA receptor positive allosteric modulators in subcat using Cat-a-lot |
||
(16 intermediate revisions by 14 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
⚫ | |||
{{Drugbox |
|||
| |
|||
| Watchedfields = changed |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Clinical data--> |
|||
| tradename = |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| legal_CA = Schedule IV |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
|||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = H223WHY93B |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID |
| ChemSpiderID = 13723 |
||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|||
| InChI = 1/C11H15BrN2O3/c1-4-6(2)11(5-7(3)12)8(15)13-10(17)14-9(11)16/h6H,3-5H2,1-2H3,(H2,13,14,15,16,17) |
|||
⚫ | |||
| InChIKey = FWZMBTIUIQUJFF-UHFFFAOYAI |
|||
| ChEMBL = 469253 |
| ChEMBL = 469253 |
||
<!--Chemical data--> |
|||
⚫ | |||
⚫ | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C11H15BrN2O3/c1-4-6(2)11(5-7(3)12)8(15)13-10(17)14-9(11)16/h6H,3-5H2,1-2H3,(H2,13,14,15,16,17) |
| StdInChI = 1S/C11H15BrN2O3/c1-4-6(2)11(5-7(3)12)8(15)13-10(17)14-9(11)16/h6H,3-5H2,1-2H3,(H2,13,14,15,16,17) |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = FWZMBTIUIQUJFF-UHFFFAOYSA-N |
| StdInChIKey = FWZMBTIUIQUJFF-UHFFFAOYSA-N |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| molecular_weight = 303.15 g/mol |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
}} |
}} |
||
'''Butallylonal''' is a [[barbiturate]] derivative invented in the 1920s.<ref>{{cite patent|country=US|number=1739662}}</ref> It has [[sedative]] properties, and was used primarily as an anaesthetic in [[veterinary]] medicine.<ref>{{cite journal | doi = 10.1007/BF01907782 | |
'''Butallylonal''' is a [[barbiturate]] derivative invented in the 1920s.<ref>{{cite patent|country=US|number=1739662}}</ref> It has [[sedative]] properties, and was used primarily as an anaesthetic in [[veterinary]] medicine.<ref>{{cite journal | doi = 10.1007/BF01907782 | vauthors = Mittmann U, Schmidt HD, Schmier J, Wirth RH | title = Hemorrhagic shock with fixed hypotension and with spontaneous recovery of blood pressure. A comparison of two shock models | journal = Basic Research in Cardiology | year = 1976 | volume = 71 | issue = 1 | pages = 47–59 | pmid = 1259685| s2cid = 5567045 }}</ref> Butallylonal is considered similar in effects to [[pentobarbital]] but is longer in action, being considered an intermediate-acting barbiturate rather than short-acting. |
||
== References == |
== References == |
||
{{reflist}} |
{{reflist}} |
||
{{ |
{{GABAAR PAMs}} |
||
⚫ | |||
[[Category:Barbiturates]] |
[[Category:Barbiturates]] |
||
[[Category:Organobromides]] |
[[Category:Organobromides]] |
||
[[Category: |
[[Category:Alkene derivatives]] |
||
⚫ | |||
[[de:Butallylonal]] |